Yayınlar & Eserler

Yayın Ağı
Makaleler 21
Tümü (21)
SCI-E, SSCI, AHCI (19)
SCI-E, SSCI, AHCI, ESCI (19)
Scopus (20)
TRDizin (2)

1. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.
International Journal of Cancer , cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)

2. The Impact of Smoking on Nivolumab Outcomes in Renal Cell Carcinoma: Real-World Data from the Turkish Oncology Group Kidney Cancer Consortium (TKCC).

Sertesen Camoz E., Bolek H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., et al.
The oncologist , cilt.30, 2025 (SCI-Expanded, Scopus)

3. Extramedullary disease in multiple myeloma at diagnosis and over the course of the disease.

Guliyev M., Tunc A., Yılmaz U., Kucukyurt S., Ozmen D., Elverdi T., et al.
International journal of hematology , cilt.122, ss.73-82, 2025 (SCI-Expanded, Scopus)

4. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

BÖLEK H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.
CANCER COMMUNICATIONS , cilt.45, sa.5, ss.572-576, 2025 (SCI-Expanded, Scopus)

5. Prognostic Significance of Inflammatory and Nutritional Biomarkers in Patients with Metastatic Gastric Cancer

Guliyev M., Alan Ö., Safarov S., Alkan Şen G., Günaltılı M., Fidan M. C., et al.
Journal of oncological sciences , cilt.11, sa.1, ss.14-21, 2025 (TRDizin) Creative Commons License

6. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

Topal A., Akdag G., Yildirim S., Kinikoglu O., Isik D., Yildirim G., et al.
Medicina (Lithuania) , cilt.61, sa.3, 2025 (SCI-Expanded, Scopus)

7. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors.

Güren A. K., Guliyev M., Alan Ö., Çadırci K., Belevi İ. N., Gültürk İ., et al.
Journal of clinical medicine , cilt.14, sa.4, 2025 (SCI-Expanded, Scopus) Creative Commons License

8. Effects of immune related adverse events and corticosteroids on the outcome of patients treated with immune checkpoint inhibitors

Şen G. A., Öztaş N. Ş., Değerli E., Safarov S., Guliyev M., Bedir Ş., et al.
SCIENTIFIC REPORTS , cilt.15, sa.1, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. The Impact of Progesterone Receptor Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with First-Line CDK4/6 Inhibitors

Guliyev M., Güren A. K., Özge E., Çolak R., Majidova N., Alkan Şen G., et al.
CANCERS , cilt.17, sa.4, 2025 (SCI-Expanded, Scopus) Creative Commons License

10. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study.

Majidova N., Arak H., Ozalp F. R., Bas O., Koker G. O., Ozmarasalı E. B., et al.
Scientific reports , cilt.15, sa.1, ss.3200, 2025 (SCI-Expanded, Scopus)

11. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Yildirim H. C., Kapar C., KÖKSAL B., Seyyar M., Sanci P. C., Guliyev M., et al.
JOURNAL OF CHEMOTHERAPY , cilt.37, sa.1, ss.69-75, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey.

Majidova N., Aghamaliyeva S., Guliyev M., Dinc G., AKYILDIZ A., Ozcan E., et al.
Journal of chemotherapy (Florence, Italy) , cilt.37, sa.8, ss.735-740, 2025 (SCI-Expanded, Scopus)

13. Could macrocytosis predict survival In advanced breast cancer patients that were treated with CDK 4–6 inhibitors?

Gültürk I., Colak R., Kapar C., Guliyev M., Yıldırım C., Yilmaz M.
Breast , cilt.78, 2024 (SCI-Expanded, Scopus)

14. Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors.

Şen G. A., Öztaş N. Ş., Değerli E., Guliyev M., Can G., Turna H., et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico , cilt.26, sa.12, ss.3264-3271, 2024 (SCI-Expanded, Scopus)

15. Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer.

Alkan Şen G., Şentürk Öztaş N., Değerli E., Guliyev M., Turna H., Özgüroğlu M.
Tumori , cilt.110, sa.6, ss.437-442, 2024 (SCI-Expanded, Scopus)

16. Obesity Is an Independent Prognostic Factor That Reduced Pathological Complete Response in Operable Breast Cancer Patients.

Guliyev M., Alan Ö., Günaltılı M., Safarov S., Fidan M. C., Alkan Şen G., et al.
Medicina (Kaunas, Lithuania) , cilt.60, sa.12, 2024 (SCI-Expanded, Scopus) Creative Commons License

17. The impact of HER2-low status on pathological complete response and disease-free survival in early-stage breast cancer.

Şen G. A., AYDIN E., Guliyev M., Öztaş N. Ş., Değerli E., DEMİRCİ N. S., et al.
BMC cancer , cilt.24, sa.1, ss.1311, 2024 (SCI-Expanded, Scopus)

18. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

Akyildiz A., GÜVEN D. C., Koksal B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.281, sa.9, ss.4991-4999, 2024 (SCI-Expanded, Scopus) Creative Commons License

19. Efficacy and Safety of Ixabepilone in Metastatic Breast Cancer After Multiple Treatments: Analysis Based on Real-World Data

Akdağ G., Alan Ö., Doğan A., Yildirim S., Kinikoğlu O., Majidova N., et al.
Journal of oncological sciences , cilt.10, sa.2, ss.89-96, 2024 (TRDizin)

20. The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study

Guliyev M., Şen G. A., Gültürk İ., Majidova N., Akdağ G., Ahadzade A., et al.
BREAST CANCER RESEARCH AND TREATMENT , cilt.205, sa.3, ss.633-640, 2024 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma

21. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report

Samanci N. S., Guliyev M., Degerli E., Celik E., Turna Z. H.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.18, sa.3, ss.792-794, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Retrospective Analysis of Prognostic Factors and Survival in Multiple Myeloma Patients Aged 65 Years or Older at Diagnosis in a Real-Life Setting and a Proposed New Staging System

TUNÇ A., GULIYEV M., Tekin T. O., Kucukyurt S., YILMAZ U., NUHOĞLU KANTARCI F. E., et al.
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, Amerika Birleşik Devletleri, 10 - 13 Aralık 2022, ss.12518-12519, (Özet Bildiri)
Metrikler

Yayın

22

Yayın (WoS)

20

Yayın (Scopus)

20

Atıf (WoS)

55

H-İndeks (WoS)

5

Atıf (Scopus)

64

H-İndeks (Scopus)

5

Atıf (Scholar)

19

H-İndeks (Scholar)

3

Açık Erişim

6
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER